GLUE vs SRPT · rev $13.2M vs rev $1.13B
Monte Rosa Therapeutics Inc (GLUE) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Monte Rosa Therapeutics Inc (GLUE) is a biotechnology company listed on NASDAQ.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported GLUE revenue for 2026-06-30 was $13.2M. Net income was -$87.9M. GLUE currently screens at market cap $1.56B.
Latest reported SRPT revenue for 2026-06-30 was $1.13B. Net income was $326.1M. Revenue was up 54.9% from 2026-03-31 to 2026-06-30. SRPT currently screens at market cap $2.34B.
GLUE currently screens at market cap $1.56B. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the GLUE and SRPT stock pages for the full models.
Not investment advice.